What you would otherwise miss
Recalls, reports and gaps, matched to what you take.
“product labeled as tirzepatide contains testosterone cypionate.”
Preview my compounds — freeRead a sample report
Free: counts in each category. The records themselves are Pro.
Example weekly record
SenzuExample profile — not a real member
Weekly record — example profile: semaglutide
Built from Senzu’s public sample. Example profile: semaglutide and BPC-157.
What reaches you, and what usually does not
Papers, FDA actions, side effects, certificates and prices that name your compounds, each dated and sourced.
- Issued
- Earliest paper published
- Latest paper published
What the research measured, and in whom
Stated in the paper’s own terms, with the kind of study beside it.
Randomized trial
Semaglutide: the trial reported more weight loss than placebo
In this published trial, people on the study medicine lost more weight after 68 weeks than people on placebo (−14.9% vs −2.4%).
Who was studied · limit · 2 sources
Who was studied 1,961 adults with overweight or obesity, without diabetes.
Limit The result does not describe compounded, research-labelled, or other non-trial semaglutide products.
- PubMedpublished
- ClinicalTrials.govpublished
Side effects, as the study reported them
As the trial reported it, beside its comparison. Not a verdict on a compound.
Randomized trial
Semaglutide: the trial reported more retinopathy complications
This published trial in people with type 2 diabetes reported more Event Adjudication Committee–confirmed diabetic retinopathy complications with semaglutide than with placebo: 50 (3.0%) versus 29 (1.8%).
Who was studied · limit · 3 sources
Who was studied 3,297 adults with type 2 diabetes on a standard-care regimen. 2,735 (83.0%) had established cardiovascular disease, chronic kidney disease, or both.
Limit Industry funded by Novo Nordisk. The trial was designed for cardiovascular outcomes; diabetic retinopathy complications were a secondary microvascular endpoint.
- PubMedpublished
- PubMed Centralpublished
- PubMed Centralpublished
Where the evidence stops
Where the evidence runs out, the record says so. A gap is not evidence of safety.
Systematic review
BPC-157: this review had almost no human evidence
This 2025 review looked at 36 studies: 35 in animals or lab dishes, and one human report of 12 people.
Absence No included study assessed BPC-157 safety in humans.
Who was studied · limit · 2 sources
Who was studied Mostly animal and lab studies. One human report of 12 people with knee pain.
Limit No clinical safety data were found. Absence of reported animal acute toxicity is not evidence of human safety.
- PubMed Centralpublished
- PubMedpublished
Whether anyone tested the vial
Lab certificates on record for each compound, or a line saying none is.
Absence No certificate appears in this public sample.
What the same compound is listed for
Listed prices on two dates, vendors in alphabetical order.
Absence This public sample lists no vendor prices.
What changed since last Monday
New items carry two dates: published, and recorded by Senzu.
- Last checked
- Schedule
- A static public sample.
Why it matters
The FDA, in its own words.
Testing revealed there was no oxytocin in the IV bag.
Source
FDA enforcement report (openFDA drug enforcement), report date 2025-10-22, recall initiated 2025-09-16; held in Senzu’s fda_regulatory records. Reason quoted verbatim after its category prefix; firm not named. Checked .
205 of the 280 FDA recall reports Senzu holds give a reason that concerns sterility.
Source
Senzu fda_regulatory records (raw_documents, source 5): 280 reports dated 2012-07-25 to 2026-05-27; 205 whose reason_for_recall matches “steril”. Queried 2026-10-11. Checked .
46 published since January 2025 name a GLP-1: semaglutide, tirzepatide, liraglutide or retatrutide.
Source
Senzu fda_regulatory records, published_at on or after 2025-01-01, payload naming semaglutide, tirzepatide, liraglutide or retatrutide. Queried 2026-10-11. Checked .
A recall covers the lots it names. No recall on record does not mean a compound is safe.
About these records
Quoted from FDA enforcement reports Senzu holds. No firm is named.
For Pro members
Your week’s records, in one place.
Sorted by kind, dated. Never scored or ranked.
Listed alphabetically. The order is not a priority. A quiet week does not mean a compound is safe.
- Certificates for your compounds
- New researchNew since your last visitExample dateA study record, its kind named as the paper describes it.
- Price and availability changesNew since your last visit
- Records naming your conditions
- Regulatory actionsNothing new — a quiet week does not mean a compound is safe.
- Reported side effects
- This week’s update
- Your compounds and your medications
What each section lists
- Certificates for your compounds
- Lab certificates on your compounds, or a dated line saying none appears.
- New research
- Trials, reviews and observational studies, with the kind of study named.
- Price and availability changes
- Listed prices on two dates, side by side, vendors alphabetical.
- Records naming your conditions
- Side-effect and contraindication reports naming a condition on your profile.
- Regulatory actions
- Enforcement reports naming your compounds, the agency’s classification quoted.
- Reported side effects
- Side effects reported for your compounds: how many reports, and what kind.
- This week’s update
- The reviewed weekly note, every claim linked to its record.
- Your compounds and your medications
- Reports naming your compound beside a listed medication. Not assessed for you.
On record
- 350 vendors
- 117 certificates
- 12 peptides
- No shop on this page
Records, compound by compound
One record per compound you take.
Side-effect records, compound by compound. Your own counts are in the free preview.
Record 1 of 8: Semaglutide
Example
Weekly record — Semaglutide
2,998 side-effect records
Most named
- Nausea 109
- Constipation 51
- Vomiting 48
In your free preview
- New research
- Certificates for your compounds
- Price and availability changes
- Regulatory actions
As of
Preview my compounds — freeExample — not a real member. A count of records, not a rate.
Built from these sources
- Europe PMC
- ClinicalTrials.gov
- openFDA adverse event reports
- FDA enforcement reports
- r/semaglutide
- r/tirzepatide
- r/peptides
- r/glp1
What every record includes
- Dated sources
- Study type on every finding
- Gaps listed, not hidden
- No scores, rankings or advice
Plans
Senzu Pro: every record behind your counts, a weekly email matched to your profile, the vendor directory and prices, alerts and the research assistant.
Continue to checkout — monthly
Renews until cancelled. Cancel any time from your account.
Billing details
The listed amount includes tax.
Renews at the same interval until cancelled. Existing members cancel through the Stripe billing portal from the account page. Access continues through the current paid period. Buying, signing in, or revisiting a page does not reactivate a suppressed email status.
Offer limits
- Pro is the existing Senzu subscription, not a separate report product.
- The weekly email needs a research profile; there is no general brief.
- No personal intel report, prescriber document or personal timeline today.
- No guaranteed weekly send, nor notice of every regulatory action.
- Not medical advice, a safety, purity or legality rating, or an endorsement.
- Senzu records no vendor revenue; the disclosure page covers funding.
Questions
Why would I need this?
Recalls, side-effect tables and lab certificates come out in different places on different days. Senzu puts the ones naming your compounds on one dated page, linked to the originals.
Will Senzu tell me whether something is safe?
No. Senzu reports what was published and when, with the link. It never scores, ranks, endorses or advises, and gives no dosing information. A quiet week does not mean a compound is safe.
What is in the free preview?
How many of Senzu’s records match your profile in each category, and where it holds none. Every profile question is optional. The records themselves are Pro.
What does Pro include?
The records behind your counts, a weekly email matched to your profile, the full vendor directory and prices, price and certificate alerts, and more research-assistant questions.
When would I receive updates?
Every Monday. A week with nothing new on your profile gets a short note saying so.
How do I cancel?
From your account page, through the Stripe billing portal. Access runs to the end of the paid period.
How do I contact Senzu?
Through the Corrections and Disclosure pages linked in the footer.
Senzu Pro
Read what was published. Then decide for yourself.
Sources, dates and gaps stay on the page.